Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Gastrointestinal Motility Disorders

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...

Gastric Motility

Gastric Motility

Gastric motility is the coordinated contraction and relaxation of stomach muscles that convert ingested food into chyme, a semi-liquid substance ready for further digestion in the intestines. The process begins with the vagus nerve inducing the relaxation of the smooth muscles in the fundus and body of the stomach, allowing these regions to expand and accommodate up to approximately 1.5 liters of food and liquid.
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gastric electrophysiology.

Expert review of gastroenterology & hepatology·2026

Same author

Predominant Symptom in Gastroparesis: Relationships to Quality of Life, Treatments, and Outcome.

Neurogastroenterology and motility·2026

Same author

Accelerometric Assessment of Gastric Contractility Using the Atmo Wireless Motility Capsule.

Neurogastroenterology and motility·2026

Same author

Revisiting the Incidence of Tardive Dyskinesia With Oral Metoclopramide Use: A Real-World Epidemiology Study (2011-2020).

Neurogastroenterology and motility·2026

Same author

Combined Gastric Electrical Stimulation and Pyloroplasty in Gastroparesis: A Randomized Clinical Trial.

JAMA network open·2025

Same author

Transcutaneous Electrical Acustimulation Improves Gastroparesis Symptoms and Ameliorates Gastric Pace-Making Activity in Patients With Diabetic Gastroparesis.

Neurogastroenterology and motility·2025

Search research articles

Related Experiment Video

Updated: May 21, 2026

Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test

Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [¹³C]-octanoic Acid Breath Test

Published on: March 23, 2013

Prokinetics in diabetic gastroparesis.

Reza A Hejazi¹, Richard W McCallum, Irene Sarosiek

¹Department of Internal Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, 79905, USA. Abbaszdehhejazi.reza@ttuhsc.edu

Current Gastroenterology Reports

|June 13, 2012

Summary

Diabetic gastroparesis, a complication of diabetes, causes delayed stomach emptying. Current treatments focus on prokinetic medications, with new drugs like ghrelin agonists showing future promise.

More Related Videos

Gastrointestinal Motility Monitor (GIMM)

Gastrointestinal Motility Monitor (GIMM)

Published on: December 1, 2010

Related Experiment Videos

Last Updated: May 21, 2026

Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test

Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [¹³C]-octanoic Acid Breath Test

Published on: March 23, 2013

Gastrointestinal Motility Monitor (GIMM)

Gastrointestinal Motility Monitor (GIMM)

Published on: December 1, 2010

Area of Science:

Gastroenterology
Endocrinology
Pharmacology

Background:

Diabetic gastroparesis is a recognized complication of type 1 and type 2 diabetes.
Characterized by delayed gastric emptying without mechanical obstruction, it presents with symptoms like nausea, vomiting, and weight loss.
Recent years have seen advances in understanding its pathophysiology and diagnostic methods.

Purpose of the Study:

To summarize current knowledge on prokinetic medications for diabetic gastroparesis.
To review available and investigational prokinetic drugs.
To highlight potential future treatments, including ghrelin agonists and novel 5-HT4 agonists.

Main Methods:

Literature review of prokinetic medications for diabetic gastroparesis.
Emphasis on currently available drugs and those in clinical investigation.
Focus on agents in advanced clinical trials.

Main Results:

Prokinetic medications are the primary therapeutic strategy for improving symptoms by enhancing gastric emptying.
Several new agents are under investigation, with some in advanced trials.
Ghrelin agonists and newer 5-HT4 agonists (with reduced cardiac side effects) are promising future treatments.

Conclusions:

Prokinetic agents are central to managing diabetic gastroparesis symptoms.
Ongoing research is yielding new therapeutic options, including novel 5-HT4 agonists and ghrelin agonists.
These advancements offer hope for improved treatment of this diabetic complication.